Back to Directory
Last Updated: 07/06/2026

Serenatis Bio

Cambridge
Founded 2024
Precision small molecule drugs for obsessive-compulsive disorder

Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD).

Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to treatments by biological subtype.

The lead programme, SB001, is an mGluR2/3 modulator developed from research with the University of Cambridge.

BiotechDrug DiscoveryNeurology
Small Molecule DrugsNeuropsychiatry

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page